Edge Therapeutics (EDGE) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Leerink Partners Cuts Price Target on Edge Therapeutics (EDGE) Following 4Q Results
March 8, 2016 1:51 PM ESTLeerink Partners maintained an Outperform rating on Edge Therapeutics (NASDAQ: EDGE), and cut the price target to $24.00 (from $27.00), following the company's 4Q. EDGE reported a net loss and EPS of $8.1M and ($0.30), which was largely in-line with Leerink's estimates of $7.9M and ($0.28).
Analyst... More
